Hamlet BioPharma (BST:7ZT) - Stock Price, News & Analysis

7ZT Stock Overview

Engages in the development of drugs for the treatment and prevention of cancer in Sweden. More details

7ZT fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Earnings have declined by 17% per year over past 5 years

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (SEK-9K)

Highly volatile share price over the past 3 months compared to the German market

+ 2 more risks

Hamlet BioPharma AB (publ) Competitors

4SC

DB:VSC

€50.2m

Medigene

XTRA:MDG1

€17.4m

Heidelberg Pharma

XTRA:HPHA

€105.8m

2invest

XTRA:2INV

€62.7m

Price History & Performance

Summary of all time highs, changes and price drops for Hamlet BioPharma
Historical stock prices
Current Share Price	SEK 0.25
52 Week High	SEK 0.41
52 Week Low	SEK 0.20
Beta	1.12
11 Month Change	-26.76%
3 Month Change	-3.86%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	315.00%

Recent updates

Shareholder Returns

	7ZT	DE Biotechs	DE Market
7D	13.7%	-1.1%	1.1%
1Y	n/a	-18.8%	7.2%

Return vs Industry: Insufficient data to determine how 7ZT performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 7ZT performed against the German Market.

Price Volatility

Is 7ZT's price volatile compared to industry and market?
7ZT volatility
7ZT Average Weekly Movement	14.7%
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 7ZT's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 7ZT's weekly volatility has decreased from 116% to 15% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1999	8	Petter Lindqvist	www.hamletpharma.com

Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company’s products under development include Alpha1H for the treatment of bladder cancer and brain tumors; and BAMLET for the treatment of colon and oral cancer.

Hamlet BioPharma AB (publ) Fundamentals Summary

How do Hamlet BioPharma's earnings and revenue compare to its market cap?
7ZT fundamental statistics
Market cap	€46.26m
Earnings (TTM)	-€3.75m
Revenue (TTM)	n/a

9,999x

P/S Ratio

-12.3x

P/E Ratio

Is 7ZT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7ZT income statement (TTM)
Revenue	-SEK 8.51k
Cost of Revenue	SEK 0
Gross Profit	-SEK 8.51k
Other Expenses	SEK 43.24m
Earnings	-SEK 43.25m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.26
Gross Margin	100.00%
Net Profit Margin	508,198.31%
Debt/Equity Ratio	0%

How did 7ZT perform over the long term?

See historical performance and comparison

Hamlet BioPharma BST:7ZT Stock Report